Key Inclusion Criteria:

          -  Subjects with advanced or metastatic solid tumours who have completed treatment with
             first line therapy:

               1. Epithelial ovarian, fallopian tube, or peritoneal cancer

               2. Hepatocellular carcinoma

               3. Non-small cell lung cancer

               4. Urothelial cancer

               5. Microsatellite instability high solid tumours, other than the above indications

          -  Radiologic and/or biochemical evidence of disease progression

          -  Completion of pre-treatment tumour biopsy

          -  Must have measurable disease by RECIST v1.1

          -  Ambulatory with an ECOG 0-1

          -  Life expectancy ≥ 6 months

          -  Meet protocol-specified laboratory requirements

        Key Exclusion Criteria:

          -  Chemotherapy or immunotherapy within treatment within 28 days of start of study
             treatment

          -  Radiotherapy within treatment within 2 weeks of start of study treatment

          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent
             directed to another stimulatory or co-inhibitory T cell receptor where subject was
             discontinued from that treatment due to a Grade 3 or higher immune-related toxicity

          -  For NSCLC subjects: Known EGFR mutations or ALK rearrangements

          -  Prior receipt of survivin-based vaccine(s) and/or immunotherapies

          -  Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma
             in situ, or controlled bladder cancer

          -  Clinical ascites or pleural fluid that cannot be managed

          -  Malignant bowel obstruction or recent history of bowel obstruction

          -  For OvCa, subjects with any single lesion greater than 5 cm

          -  Autoimmune disease requiring treatment within the last two years (except replacement
             therapy)

          -  Recent history of thyroiditis

          -  Any history of (non-infectious) pneumonitis that required steroid therapy or current
             pneumonitis

          -  Presence of a serious acute or chronic infection

          -  Active CNS metastases and/or carcinomatous meningitis

          -  GI condition that might limit absorption of oral agents

          -  Allogenic tissue/solid organ transplant

          -  Other serious intercurrent chronic or acute illness, including myocardial infarction
             or cerebrovascular event within 6 months

          -  Ongoing treatment with steroid therapy or other immunosuppressive

          -  Receipt of live attenuated vaccines

          -  Acute or chronic skin and/or microvascular disorders

          -  Edema or lymphedema in the lower limbs > grade 2

          -  Severe hypersensitivity (≥ Grade 3) to pembrolizumab